B7.2-Ig fusion proteins enhance IL-4-dependent differentiation of tumor-sensitized CD8+ cytotoxic T lymphocyte precursors

International Immunology

Volumn 17, Issue 8, 2005, Pages 1071-1079

  Hiraoka, Shin Ichiro ^a   Takeuchi, Noritami ^a   Bian, Yang ^a   Nakahara, Hirokazu ^b   Kogo, Mikihiko ^b   Dunussi Joannopoulos, Kyriaki ^c   Wolf, Stanley ^c   Ono, Shiro ^a   Fujiwara, Hiromi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c PFIZER INC   (United States)

Author keywords

CD40L; Costimulation; Th1 Tc2; Th2 Tc2; Tumor immunity

Indexed keywords

CD40 LIGAND; CD8 ANTIGEN; HYBRID PROTEIN; INTERLEUKIN 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL CULTURE; CELL DIFFERENTIATION; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; GENE EXPRESSION; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SENSITIZATION; SIGNAL TRANSDUCTION; SPLEEN CELL;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD86; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELLS, CULTURED; IMMUNOGLOBULINS; INTERFERON TYPE II; INTERLEUKIN-4; LYMPHOCYTE ACTIVATION; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; NEUTRALIZATION TESTS; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 23844536884     PISSN: 09538178     EISSN: None     Source Type: Journal    
DOI: 10.1093/intimm/dxh288     Document Type: Article

References (40)

1. Bevan, M. J. 1976. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J. Exp. Med. 143:1283.
2. + T cell responses to infectious agents, tumors, transplants, and vaccines. Adv. Immunol. 73:1.
3. Heath, W. R. and Carbone, F. R. 1999. Cytotoxic T lymphocyte activation by cross-priming. Curr. Opin. Immunol. 11:314.
4. Huang, A. Y., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D. and Levitsky, H. 1994. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264:961.
5. - dendritic cells cross-prime cytotoxic T cells in vivo. J. Exp. Med. 192:1685.
6. + T cell help. J. Exp. Med. 186:65.
7. + T-helper and a T-killer cell. Nature 393:474.
8. Bennett, S. R., Carbone, F. R., Karamalis, F., Flavell, R. A., Miller, J. F. and Heath, W. R. 1998. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393:478.
9. Schoenberger, S. P., Toes, R. E., van-der-Voort, E. I., Offringa, R. and Melief, C. J. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393:480.
10. Schuler, T., Qin, Z., Ibe, S., Noben-Trauth, N. and Blankenstein, T. 1999. T helper cell type 1-associated and cytotoxic T lymphocyte-mediated tumor immunity is impaired in interleukin 4-deficient mice. J. Exp. Med. 189:803.
11. + T cells. J. Exp. Med. 194:1767.
12. + T cells and dependence on IL-4 production. J. Immunol. 172:1347.
13. Greenberg, P. D. 1991. Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49:281.
14. Aruga, A., Aruga, E., Tanigawa, K., Bishop, D. K., Sondak, V. K. and Chang, A. E. 1997. Type 1 versus type 2 cytokine release by Vβ T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role. J. Immunol. 159:664.
15. Sturmhoefel, K., Lee, K., Gray, G. S. et al. 1999. Potent activity of soluble B7-IgG fusion proteins in therapy of established tumors and as vaccine adjuvant. Cancer Res. 59:4964.
16. Inaba, M., Inaba, K., Fukuba, Y. et al. 1995. Activation of thymic B cells by signals of CD40 molecules plus interleukin-10. Eur. J. Immunol. 25:1244.
17. Wysocka, M., Kubin, M., Vieira, L. Q. et al. 1995. Interleukin-12 is required for interferon-γ production and lethality in lipopolysaccharide-induced shock in mice. Eur. J. Immunol. 25:672.
18. -,T cell subsets to express IL-18 receptor and produce IFN-γ in response to IL-18. J. Immunol. 160:3759.
19. Kitagawa, S., Iwata, H., Sato, S., Shimizu, J., Hamaoka, T. and Fujiwara, H. 1991. Heterogenous graft rejection pathways in class I major histocompatibility complex-disparate combinations and their differential susceptibility to immunomodulation induced by intravenous presensitization with relevant alloantigens. J. Exp. Med. 174:571.
20. Wunderlich, J., Shearer, G. M. and Livingstone, A. 2002. Induction and measurement of cytotoxic T lymphocyte activity. In Coligan, J. E., Kruisbeek,A. M., Margulies,D. H., Shevach, E. M., Strober,W., eds, Current Protocols in Immunology, p. 3.11.1. Wiley & Sons, New York.
21. + T cells. Int. Immunol. 17:73.
22. + T cell activity. J. Immunol. 148:648.
23. Yamamoto, N., Zou, J. P., Li, X. F. et al. 1995. Regulatory mechanisms for production of IFN-γ and TNF by antitumor T cells or macrophages in the tumor-bearing state. J. Immunol. 154:2281.
24. Linsley, P. S. and Ledbetter, J. A. 1993. The role of the CD28 receptor during T cell responses to antigen. Annu. Rev. Immunol. 11:191.
25. Lenschow, D. J., Walunas, T. L. and Bluestone, J. A. 1996. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14:233.
26. Zou, J. P., Yamamoto, N., Fujii, T. et al. 1995. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: Response is correlated with a striking reversal of suppressed IFN-γ production by anti-tumor T cells. Int. Immunol. 7:1135.
27. Nastala, C. L., Edington, H. D., McKinney, T. G. et al. 1994. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J. Immunol. 153:1697.
28. Yu, W. G., Yamamoto, N., Takenaka, H. et al. 1996. Molecular mechanisms underlying IFN-γ-mediated tumor growth inhibition induced during tumor immunotherapy with rIL-12. Int. Immunol. 8:855.
29. + T cells. In Paul, W. E., ed., Fundamental Immunology, 4th edn, p. 879. Lippincott-Raven Publishers, Philadelphia, PA.
30. Tepper, R. I., Pattengale, P. K. and Leder, P. 1989. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57:503.
31. + cytotoxic T-lymphocyte activation in mice. Cancer Res. 56:5005.
32. + T cell-dependent tumor eradication in vivo. J. Immunol. 165:5495.
33. Nishimura, T., Iwakabe, K., Sekimoto, M. et al. 1999. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J. Exp. Med. 190:617.
34. Dobrzanski, M. J., Reome, J. B. and Dutton, R. W. 2001. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection. J. Immunol. 167:424.
35. + T cell subpopulations in established pulmonary metastases. J. Immunol. 162:6671.
36. Lindstein, T., June, C. H., Ledbetter, J. A., Stella, G. and Thompson, C. B. 1989. Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Science 244:339.
37. Webb, L. M. and Feldmann, M. 1995. Critical role of CD28/B7 costimulation in the development of human Th2 cytokine-producing cells. Blood 86:3479.
38. + T cells with CD80 or CD86 rather than anti-CD28 leads to a Th2 cytokine profile. J. Immunol. 165:6908.
39. Salomon, B. and Bluestone, J. A. 2001. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu. Rev. Immunol. 19:225.
40. + T cells. Blood 105:1574.